Key result
Testing for inherited thrombophilia in venous thromboembolism should generally be avoided, as it does not alter anticoagulant therapy and acute phase testing yields erroneous results.
Why the study?
Does testing for inherited thrombophilia alter management in patients with venous thromboembolism?
Does testing for inherited thrombophilia alter management in patients with venous thromboembolism?
Routine testing for inherited thrombophilia in VTE patients is not recommended as it does not alter anticoagulant management and is prone to errors if done acutely.
May avoid unnecessary testing and misinterpretation in acute VTE; leaves open selective testing in high-risk subgroups.
Testing for inherited thrombophilia in patients with venous thromboembolism is one of the most common genetic testing options prescribed by clinicians. Despite the large evidence base for the relationship of hereditary hemostasis disorders with the risk of venous thrombosis, most patients should not be tested. Performing tests in the acute phase of thrombosis or during anticoagulant therapy leads to erroneous results. The choice of anticoagulant therapy regimen and its duration are not specified by the presence of hereditary thrombophilia. The test results can be useful for increasing medication adherence of patient, determining the cause of thrombosis, especially at a young age or in atypical localization.
No takes yet. Share an insight, caveat, or question.
Зотова et al. (2020) conducted a review in venous thromboembolism. Testing for inherited thrombophilia was evaluated. Testing for inherited thrombophilia in venous thromboembolism should generally be avoided, as it does not alter anticoagulant therapy and acute phase testing yields erroneous results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: